Mr Hancock told the Covid Inquiry, earlier in January, that Britain’s vaccine manufacturing capacity was “weak”, adding: “having that manufacture and fill and finish onshore, physically within the UK, is critical in the way that it simply isn’t in normal times”.
AstraZeneca cancels £450m vaccine plant in UK after Government ‘own goal’ in blow to Rachel Reeves growth plan
